Salarin C inhibits the maintenance of chronic myeloid leukemia progenitor cells

References

• Abruzzese E, Breccia M, Latagliata R. Second-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukaemia (CML). BioDrugs 2014; 28: 17-26; PMID:24043361; http://dx.doi.org/10.1007/s40259-013-0056-z
   PubMed Web of Science ®Google Scholar
• Tang M, Foo J, Gönen M, Guilhot J, Mahon FX, Michor F. Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials. Haematologica 2012; 97: 1553-61; PMID:22419579; http://dx.doi.org/10.3324/haematol.2012.062844
   PubMed Web of Science ®Google Scholar
• Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004; 104: 2204-05; PMID:15377577; http://dx.doi.org/10.1182/blood-2004-04-1335
   PubMed Web of Science ®Google Scholar
• Breccia M, Alimena G. Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: treatment-free remission as a new goal in chronic myeloid leukemia. Cancer Lett 2014; 347: 22-8; PMID:24508029; http://dx.doi.org/10.1016/j.canlet.2014.01.033
   PubMed Web of Science ®Google Scholar
• Graham SM, Jørgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, Holyoake TL. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319-25; PMID:11756187; http://dx.doi.org/10.1182/blood.V99.1.319
   PubMed Web of Science ®Google Scholar
• Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, Li S. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci USA 2006; 103: 16870-875.
   Google Scholar
• Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011; 121: 396-409; PMID:21157039; http://dx.doi.org/10.1172/JCI35721
   PubMed Web of Science ®Google Scholar
• Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, Allan EK, Nicolini FE, Müller-Tidow C, Bhatia R, Brunton VG, et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 2012; 119: 1501-10; PMID:22184410; http://dx.doi.org/10.1182/blood-2010-12-326843
   PubMed Web of Science ®Google Scholar
• Zhang H, Li S. Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells. Protein Cell 2013; 4: 186-96; PMID:23483480; http://dx.doi.org/10.1007/s13238-013-2115-0
   PubMed Web of Science ®Google Scholar
• Giuntoli S, Rovida E, Barbetti V, Cipolleschi MG, Olivotto M, Dello Sbarba P. Hypoxia suppresses BCR/Abl and selects Imatinib-insensitive progenitors within clonal CML population. Leukemia 2006; 20: 1291-93; PMID:16710305; http://dx.doi.org/10.1038/sj.leu.2404224
   PubMed Web of Science ®Google Scholar
• Giuntoli S, Tanturli M, Di Gesualdo F, Barbetti V, Rovida E, Dello Sbarba P. Glucose availability in hypoxia regulates the selection of chronic myeloid leukemia progenitor subsets with different resistance to imatinib-mesylate. Haematologica 2011; 96: 204-12; PMID:21071498; http://dx.doi.org/10.3324/haematol.2010.029082
   PubMed Web of Science ®Google Scholar
• Giuntoli S, Barbetti V, Rovida E, Dello Sbarba P. Hypoxia selects bortezomib-resistant stem cells of chronic myeloid leukemia. PLoS-One 2011; 6(2): e17008; PMID:21347297.
   PubMed Web of Science ®Google Scholar
• Cipolleschi MG, Rovida E, Dello Sbarba P. The Culture-Repopulating Ability assays and incubation in low oxygen: a simple way to test drugs on leukemia stem or progenitor cells. Curr Pharm Des 2013; 19: 5374-83; PMID:23394087; http://dx.doi.org/10.2174/1381612811319300006
   PubMed Web of Science ®Google Scholar
• Rovida E, Marzi I, Cipolleschi MG, Dello Sbarba P. One more stem cell niche: how the sensitivity of chronic myeloid leukemia cells to imatinib-mesylate is modulated within a “hypoxic” environment. Hypoxia 2014; 2: 1-10.
   PubMedGoogle Scholar
• Rovida E, Peppicelli S, Bono S, Bianchini F, Tusa I, Cheloni G, Marzi I, Cipolleschi MG, Calorini L, Dello Sbarba P. The metabolically-modulated stem cell niche: a dynamic scenario regulating cancer cell phenotype and resistance to therapy. Cell Cycle 2014; 13:3169-75; PMID:25485495; http://dx.doi.org/10.4161/15384101.2014.964107
   PubMed Web of Science ®Google Scholar
• Ivanovic Z. Hypoxia or in situ normoxia: The stem cell paradigm. J Cell Physiol 2009; 219: 271-75; PMID:19160417; http://dx.doi.org/10.1002/jcp.21690
   PubMed Web of Science ®Google Scholar
• Winkler IG, Barbier V, Wadley R, Zannettino AC, Williams S, Lévesque JP. Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: serially reconstituting hematopoietic stem cells reside in distinct nonperfused niches. Blood 2010; 116: 375-85; PMID:20393133; http://dx.doi.org/10.1182/blood-2009-07-233437
   PubMed Web of Science ®Google Scholar
• Lévesque JP, Winkler IG. Hierarchy of immature hematopoietic cells related to blood flow and niche. Curr Opin Hematol 2011; 18: 220-25; ; http://dx.doi.org/10.1097/MOH.0b013e3283475fe7
   PubMed Web of Science ®Google Scholar
• Nombela-Arrieta C, Pivarnik G, Winkel B, Canty KJ, Harley B, Mahoney JE, Park SY, Lu J, Protopopov A, Silberstein LE. Quantitative imaging of haematopoietic stem and progenitor cell localization and hypoxic status in the bone marrow microenvironment. Nat Cell Biol 2013; 15: 533-44; PMID:23624405; http://dx.doi.org/10.1038/ncb2730
   PubMed Web of Science ®Google Scholar
• Spencer JA, Ferraro F, Roussakis E, Klein A, Wu J, Runnels JM, Zaher W, Mortensen LJ, Alt C, Turcotte R, et al. Direct measurement of local oxygen concentration in the bone marrow of live animals. Nature 2014; 508: 269-73; PMID:24590072; http://dx.doi.org/10.1038/nature13034
   PubMed Web of Science ®Google Scholar
• Konig H, Holtz M, Modi H, Manley P, Holyoake TL, Forman SJ, Bhatia R. Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia 2008; 22: 748-55; PMID:18273048; http://dx.doi.org/10.1038/sj.leu.2405086
   PubMed Web of Science ®Google Scholar
• Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, et al. Intergroupe Français des Leucémies Myéloïdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre STopIMatinib (STIMtrial. Lancet Oncol 2010; 11: 1029-35; PMID:20965785; http://dx.doi.org/10.1016/S1470-2045(10)70233-3
   PubMed Web of Science ®Google Scholar
• Modi H, McDonald T, Chu S, Yee JK, Forman SJ, Bhatia R. Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells. Blood 2007; 109: 5411-21; PMID:17347407; http://dx.doi.org/10.1182/blood-2006-06-032490
   PubMed Web of Science ®Google Scholar
• Bishara A, Rudi A, Aknin M, Neumann D, Ben-Califa N, Kashman Y. Salarin C, a new cytotoxic sponge-derived nitrogenous macrolide. Tetrahedron Lett 2008; 49: 4355-58; http://dx.doi.org/10.1016/j.tetlet.2008.05.038
   Web of Science ®Google Scholar
• Bishara A, Rudi A, Goldberg I, Aknin M, Neumann D, Ben-Califa N, Kashman Y. Tausalarin C: a new bioactive marine sponge-derived nitrogenous bismacrolide. Org Lett 2009; 11: 3538-41; PMID:19627102; http://dx.doi.org/10.1021/ol9011019
   PubMed Web of Science ®Google Scholar
• Zur LG, Bishara A, Aknin M, Neumann D, Ben-Califa N, Kashman Y. Derivatives of salarin A, salarin C and tulearin A–Fascaplysinopsis sp. metabolites. Mar Drugs 2013; 11: 4487-509.
   Google Scholar
• Ben-Califa N, Bishara A, Kashman Y, Neumann D. Salarin C, a member of the salarin superfamily of marine compounds, is a potent inducer of apoptosis. Invest New Drugs 2012; 30: 98-104; PMID:20734109; http://dx.doi.org/10.1007/s10637-010-9521-4
   PubMed Web of Science ®Google Scholar
• Fernandez-Capetillo O, Chen HT, Celeste A, Ward I, Romanienko PJ, Morales JC, Naka K, Xia Z, Camerini-Otero RD, Motoyama N, et al. DNA damage-induced G2-M checkpoint activation by histone H2AX and 53BP1. Nat Cell Biol 2002; 4: 993-97; PMID:12447390; http://dx.doi.org/10.1038/ncb884
   PubMed Web of Science ®Google Scholar
• Jin Z, Dicker DT, El-Deiry WS. Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle 2002; 1: 82-9; PMID:12429913; http://dx.doi.org/10.4161/cc.1.1.104
   PubMed Web of Science ®Google Scholar
• Clark SS, Perman SM, Sahin MB, Jenkins GJ, Elegbede JA. Antileukemia activity of perillyl alcohol (POH): uncoupling apoptosis from G0/G1 arrest suggests that the primary effect of POH on Bcr/Abl-transformed cells is to induce growth arrest. Leukemia 2002; 16: 213-22; PMID:11840288; http://dx.doi.org/10.1038/sj.leu.2402369
   PubMed Web of Science ®Google Scholar
• Sattler M, Salgia R, Okuda K, Uemura N, Durstin MA, Pisick E, Xu G, Li JL, Prasad KV, Griffin JD. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3′ kinase pathway. Oncogene 1996; 12: 839-46; PMID:8632906.
   PubMed Web of Science ®Google Scholar
• Feller SM. Crk family adaptors-signalling complex formation and biological roles. Oncogene 2001; 20: 6348-71; PMID:11607838; http://dx.doi.org/10.1038/sj.onc.1204779
   PubMed Web of Science ®Google Scholar
• Sedelnikova OA, Rogakou EP, Panyutin IG, Bonner WM. Quantitative detection of (125)IdU-induced DNA double-strand breaks with gamma-H2AX antibody. Radiat Res 2002; 158: 486-92; PMID:12236816; http://dx.doi.org/10.1667/0033-7587(2002)158%5b0486:QDOIID%5d2.0.CO;2
   PubMed Web of Science ®Google Scholar
• Barbetti V, Tusa I, Cipolleschi MG, Rovida E, Dello Sbarba P. AML1/ETO sensitizes via TRAIL acute myeloid leukemia cells to the pro-apoptotic effects of hypoxia. Cell Death Dis 2013; 4: e536; PMID:23492767; http://dx.doi.org/10.1038/cddis.2013.49
   PubMed Web of Science ®Google Scholar
• Kumari A, Brendel C, Hochhaus A, Neubauer A, Burchert A. Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood 2012; 119: 530-9; PMID:22101898; http://dx.doi.org/10.1182/blood-2010-08-303495
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Oncogenic resistance to growth-limiting conditions. Nat Rev Cancer 2002; 2: 221-5; PMID:11990858; http://dx.doi.org/10.1038/nrc743
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Antiangiogenic therapy and tumor progression. Cancer Cell 2004; 5: 13-7; PMID:14749122; http://dx.doi.org/10.1016/S1535-6108(03)00336-2
   PubMed Web of Science ®Google Scholar
• Cipolleschi MG, Rovida E, Ivanović Z, Praloran V, Olivotto M, Dello Sbarba P. The expansion of murine bone marrow cells preincubated in hypoxia as an in vitro indicator of their marrow repopulating ability. Leukemia 2000; 14: 735-39; PMID:10764163; http://dx.doi.org/10.1038/sj.leu.2401744
   PubMed Web of Science ®Google Scholar
• Ivanović Z, Belloc F, Faucher JL, Cipolleschi MG, Praloran V, Dello Sbarba P. Hypoxia maintains and interleukin-3 reduces the precolony-forming cell potential of dividing CD34(+ murine bone marrow cells. Exp Hematol 2002; 30: 67-73; PMID:11823039; http://dx.doi.org/10.1016/S0301-472X(01)00765-2
   PubMed Web of Science ®Google Scholar
• Ivanović Z, Bartolozzi B, Bernabei PA, Cipolleschi MG, Rovida E, Milencović P, Praloran V, Dello Sbarba P. Incubation of bone marrow cells in hypoxia ensures the maintenance of marrow-repopulating ability together with the expansion of committed progenitors. Br J Haematol 2000; 108: 424-29; PMID:10691876; http://dx.doi.org/10.1046/j.1365-2141.2000.01842.x
   PubMed Web of Science ®Google Scholar
• Giuntoli S, Rovida E, Gozzini A, Barbetti V, Cipolleschi MG, Olivotto M, Dello Sbarba P. Severe hypoxia defines heterogeneity and selects highly immature progenitors within clonal erythroleukemia cells. Stem Cells 2007; 25: 1119-25; PMID:17255519; http://dx.doi.org/10.1634/stemcells.2006-0637
   PubMed Web of Science ®Google Scholar